Press Releases

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 12, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. “This quarter we have made meaningful progress toward our goal of bringing effective and better tolerated therapies to patients battling kidney and other cancers,” said Michael Bailey, president and chief executive officer of AVEO.…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2019– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). AVEO will…

Download PDF – NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – – Company Plans Final OS Analysis in 2Q20 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2019– AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 26, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of…

Download PDF – Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients –    -Tivozanib-Nivolumab Combination Generally Well Tolerated –   – Data to be Presented at the ESMO 2019 Annual Congress –   CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 23, 2019– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the upcoming presentation of final results from the…

Download PDF – 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss Updated Results with FDA – – AVEO to Host Conference Call Today at 8:00 am Eastern Time – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 10, 2019– AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO-3 study of tivozanib in advanced kidney cancer, AVEO continues to make meaningful clinical, regulatory and strategic progress across our pipeline,”…

Download PDF TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 1, 2019– Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) and AVEO Oncology (NASDAQ: AVEO) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU. The agreement is an amendment to the terms of the 2006 tivozanib license agreement…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 29, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that Mike Ferraresso, Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m. EDT. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 15, 2019– AVEO Oncology (NASDAQ: AVEO) today announced two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois. Presentation Details Title: Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancerFirst Author: Wendy M. Swetzig, PhD, Northwestern University Feinberg School of MedicineAbstract Number: 5538Poster…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 9, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “With a successful recent equity offering, together with the triggering of a FOTIVDA® (tivozanib) milestone from EUSA, AVEO’s strengthened balance sheet provides us with a cash runway that we expect will take us…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 1, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019. The conference is being held May 7-8 in New York. About AVEO AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company seeking to advance targeted medicines…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 23, 2019– AVEO Oncology (NASDAQ:AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the reimbursement approval and commercial launch in Spain of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). Commercial launch in Spain is the third of five EU5 country…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 3, 2019– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced it has commenced an underwritten public offering of its shares of common stock, together with warrants to purchase shares of common stock. The Company intends…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced the pricing of its previously announced underwritten public offering of 21,739,131 shares of common stock and short-term warrants to purchase up to 21,739,131 shares of…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 2, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 2:10 p.m. BST. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast…

Download PDF – Data presented during poster session at the AACR 2019 Annual Meeting – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 1, 2019– AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with cytarabine in patients with relapsed and refractory acute…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 14, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2018 and provided a business update. “The results of TIVO-3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and tolerability profile among VEGF TKIs in the treatment of kidney cancer,” said Michael Bailey, president and…

Download PDF – John H. Johnson to Step Down from Board; Will Remain an Advisor to the Company – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 26, 2019– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Gregory T. Mayes to its Board of Directors. Mr. Mayes brings to the AVEO Board over 20 years of experience as a biopharmaceutical executive with deep expertise in business…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 20, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 16, 2019– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC). The data were presented by Brian Rini, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Director,…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 31, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration (FDA) not to submit a New Drug Application (NDA) for tivozanib (FOTIVDA®) with the preliminary overall survival (OS) results from the Phase 3 TIVO-3 trial. The FDA indicated that these preliminary OS results do not allay their…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium being held February 14-16, 2019 in San Francisco. Presentation…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of…

Download PDF Phase 1/2 Study will Evaluate Combination of IMFINZI® (durvalumab) and FOTIVDA® (tivozanib) in First-Line HCC CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s IMFINZI® (durvalumab),a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with FOTIVDA® (tivozanib), AVEO’s oral, once-daily, potent…

Download PDF Extends Cash Runway to Fund Planned Operations into the Third Quarter of 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 4, 2018– AVEO Oncology (NASDAQ:AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with Hercules Capital, Inc. (Hercules). The extension was granted as a result of achieving certain predefined…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 20, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. A live webcast of the presentation can be accessed by visiting…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 15, 2018– AVEO Oncology (NASDAQ: AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). In the European Union, Norway and Iceland, tivozanib is indicated for the first line…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 9, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2018 and provided a business update. “The recent announcement of positive topline results from the Phase 3 TIVO-3 study in renal cell carcinoma is transformative for AVEO, and the next step of an ongoing, multi-year effort to ensure tivozanib (FOTIVDA®)…

Download PDF – First and Only Positive Phase 3 Study in Third- and Fourth-Line RCC – – Primary Endpoint Shows 44% Improvement in Median PFS and 26% Reduction in Risk of Progression or Death (HR=0.74, p=0.02) for Tivozanib Compared to Sorafenib – – Data for Secondary Endpoint of Overall Survival Not Yet Mature;Final Analysis Planned…

Download PDF Tivozanib-Nivolumab Combination Continues to Demonstrate Favorable Efficacy and Safety Data Presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Oct. 22, 2018– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 9, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. The TiNivo study is a…

Download PDF – Analysis Initiated on the Unanimous Recommendation of the TIVO-3 Study Independent Steering Committee – – Company Expects to Report Topline Results in Approximately 6 Weeks – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 25, 2018– AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 28, 2018– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer, will participate in the following investor conferences: A live webcast of Mr. Bailey’s presentation at the Rodman & Renshaw conference can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 17, 2018– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018, which would result in aggregate gross proceeds of approximately $5.7 million before underwriting discounts. All of…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 16, 2018– AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the…

Download PDF – IND acceptance triggers $2M milestone payment from CANbridge to AVEO – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 14, 2018– AVEO Oncology (Nasdaq: AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in esophageal squamous cell cancer (ESCC). Under…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 7, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “Our U.S. registration strategy remains a key focus for AVEO, with topline readout of the Phase 3 TIVO-3 study expected in the fourth quarter of this year,” said Michael Bailey, president and chief executive officer…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 1, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 19, 2018– AVEO Oncology (NASDAQ: AVEO) today issued the following statement regarding its recentlyrevised guidance on the timing of topline data from the TIVO-3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell carcinoma. “The Company expects to report topline results from the TIVO-3 study in the fourth quarter…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 25, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution. “We believe that inclusion in the widely referenced Russell U.S. Indexes reflects the significant progress we…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 31, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conferencein New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 8, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2018 and provided a business update. “We continue to work toward reporting topline results from our Phase 3 TIVO-3 Study, which we now anticipate will occur in the third quarter of 2018. We are working closely with our contract…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 26, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following…

Download PDF Results Published in the European Journal of Cancer CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 21, 2018– AVEO Oncology (NASDAQ: AVEO) today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib (FOTIVDA®) as second-line treatment in advanced renal cell carcinoma (aRCC), in the European Journal of Cancer. The publication, titled “Efficacy of Tivozanib Treatment after Sorafenib…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 13, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2017 and provided a business update. “Last year was one of major progress for AVEO, with highlights including the first commercial launch of tivozanib (FOTIVDA®); the completion of the enrollment for TIVO-3, our U.S. registration study; the receipt of promising…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conferencein Boston on Tuesday, March 13, 2018 at 10:40 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast…

Download PDF Recommendation Triggers $2M Milestone Payment from EUSA to AVEO CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 12, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA® (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC). In the European Union, Norway and Iceland, tivozanib is indicated…

Download PDF Data Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Feb. 10, 2018– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 7, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 1, 2018– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at leading global corporations that have a focus on oncology, including Johnson &…

Download PDF Poster Presentation Delivered at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 19, 2018– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA® (tivozanib), a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in patients with advanced,…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 4, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of…

Download PDF Provides Approximately $12.1M in Additional Cash Flow Over 2018-19 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc. and its affiliates, the terms of which enable approximately an additional $12.1 million in cash flow over 2018 and 2019, when compared to the prior loan. The…

Download PDF – Enrollment complete in Phase 2 portion of Phase 1/2 TiNivo trial;Next data presentation expected at 2018 Genitourinary Cancers Symposium in February 2018- – Investigator-sponsored studies of ficlatuzumab initiated in HNSCC and Pancreatic Cancer – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 7, 2017– AVEO Oncology (NASDAQ:AVEO) today announced clinical updates for two of its oncology programs: FOTIVDA® (tivozanib), the Company’s…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 20, 2017– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experience…

Download PDF HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 15, 2017– EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC) and for adult patients who are vascular…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 8, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2017 and provided a business update. “The third quarter was a transformative period for AVEO, with the achievement of significant milestones in each of the three pillars of our global strategy for tivozanib. Notably, with the European approval of…

Download PDF Oral Presentation Delivered at the 16th International Kidney Cancer Symposium CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Nov. 6, 2017– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA®) in combination with Bristol-Myers Squibb’s nivolumab (OPDIVO®), an…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 16, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami. The TiNivo trial is a Phase 1/2 multicenter trial of FOTIVDA® (tivozanib) in combination…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 5, 2017– AVEO Oncology (NASDAQ:AVEO) today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® (tivozanib) to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Based on the results of the futility analysis, which was reviewed by…

Download PDF Exercise of Option Triggers $2.0 Million Research and Development Payment to AVEO CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Sep. 20, 2017– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), has opted into the Phase 1/2 TiNivo study. Under terms of the agreement, EUSA may utilize data from the study for…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 13, 2017– AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma in Europe, and a $0.5 million milestone payment from CANbridge related to manufacturing development activities for AV-203, AVEO’s clinical-stage ErbB3 (HER3)…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 5, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 28, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that the European Commission (EC) has approved FOTIVDA® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. Tivozanib is indicated for the first line treatment of adult patients with advanced RCC and for adult patients who are vascular endothelial growth factor…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 9, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2017, and provided a business update. “The second quarter was marked by validating events in each of the three pillars of our global tivozanib strategy: a recommendation for approval of tivozanib in advanced renal cell carcinoma (RCC)…

Download PDF Additional Resources Sufficient to Fund Planned Operations into the 4Q 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 27, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that it has secured $14 million in aggregate gross proceeds through its credit facility with Hercules Capital, Inc. (Hercules) and the sale of common stock via its at-the-market issuance sales agreement with FBR & Co. (FBR). Pursuant to its 2010…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 23, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment for patients with advanced renal cell carcinoma (RCC). The CHMP’s recommendation is now referred to the European Commission (EC). The EC, which typically…

Download PDF – Pre-planned futility analysis of the trial expected midyear 2017;topline data expected in the first quarter of 2018 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 20, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC) has…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 8, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that its Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in subjects with advanced renal cell carcinoma (RCC) has progressed to the Phase 2 portion of the trial. Advancement of the study into the Phase 2 expansion follows the…

Download PDF Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Announces Trial in Progress Poster Also Presented Highlighting Phase 3 TIVO-3 Study of Tivozanib in RCC CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 5, 2017– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc., co-development partners, today announced the presentation of results from…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 19, 2017– AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), as part of the Marketing Authorization Application (MAA) review process for tivozanib as a treatment for patients with…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 16, 2017– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017. In this role, Mr. Dallas will be responsible for the Company’s financial strategy and management as it takes steps toward the potential commercialization of tivozanib. Mr. Dallas will also serve on the executive leadership team…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 15, 2017– The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today issued the following statement regarding the passing of its Lead Director Henri A. Termeer. “We are deeply saddened at the loss of a visionary, mentor, colleague and dear friend, Henri A. Termeer. Henri’s wisdom, foresight and persistence fundamentally changed our industry, which exists…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 8, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/653,684, entitled “notch binding agents and antagonists and methods of use thereof.” Allowed under the application are composition of matter and method of use…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 4, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update. “We strengthened our balance sheet in the first quarter through an underwritten public offering, giving us the resources to potentially fund operations through the readout of our pivotal, Phase 3 TIVO-3 study…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 20, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6, 2017. Among these is a Trials in Progress presentation highlighting the ongoing Phase 3, randomized, controlled, multi-center, open-label TIVO-3 study comparing tivozanib, the Company’s potent, selective,…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 13, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the Marketing Authorization Application (MAA) for tivozanib as a first-line treatment for renal cell carcinoma. With submission of the response complete,…

Download PDF Company Provides Updated Financial Guidance CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 3, 2017– AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd., a biopharmaceutical company focused on developing western drug candidates in China and North Asia, related to a technology transfer milestone for AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. AV-203 has demonstrated preclinical activity in…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 31, 2017– AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its option to purchase 4,500,000 shares at the public offering price of $0.50 per share. The exercise of the option increased the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 28, 2017– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 28, 2017– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $15 million. All of the shares in the offering are to…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 22, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell carcinoma (RCC). The study, which will be led by the Institut Gustave Roussy in Paris, is under the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 22, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update. “TIVO-3, our lead clinical program designed to serve as the basis for a potential U.S. registration for tivozanib as a first- and third-line treatment for renal cell cancer, continues to enroll…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 23, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), has successfully completed the first safety review by the study’s Safety Monitoring Committee (SMC). The SMC concluded that no…

Download PDF – Pivotal TIVO-3 Trial Enrollment Proceeding Substantially Ahead of Schedule; Enrollment Completion Expected in June – – Phase 1/2 TiNivo Trial Sites Scheduled to Open for Enrollment in Early March – – Partner EUSA Pharma Receives Day 180 List of Outstanding Issues from EMA, Oral Explanation Expected in 2Q 2017 – CAMBRIDGE, Mass.–(BUSINESS…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 6, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017 at 8:30 AM E.T. at the Waldorf Astoria Hotel in New York City. A live webcast can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 28, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European Medicines Agency (EMA) Day 120 List of Questions. The Day 120 List of Questions were issued by the Committee for Medicinal Products…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 22, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 3:30 PM Eastern Time. The conference is being held at the New York Palace Hotel. A live webcast can be accessed by visiting the investors section of the Company’s…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016. “In the last 18 months, we have made important progress in moving forward both elements of our strategy, including our oncology pipeline, for which we have retained significant North American rights, and our non-oncology pipeline, which…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 12, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco. A live webcast can be accessed by visiting the investors section of the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.m., before the Honorable Denise J. Casper, United States Courthouse, Courtroom No. 11 of the John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, Massachusetts 02210 in the matter of Karen J. van Ingen v. AVEO Pharmaceuticals, Inc., et al., Civil Action No. 1:14-cv-11672-DJC…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 6, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 12:30 PM Eastern Time. The conference is being held at the New York Palace Hotel. A live webcast can be accessed by visiting the investors section of…

Download PDF –Phase 1/2 TiNivo Trial to Commence at the Institut Gustave Roussy in Paris- CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 4, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016. “The second quarter of 2016 marked a defining moment for AVEO, with the initiation of TIVO-3, our Phase 3 pivotal study of tivozanib in refractory advanced renal cell cancer, and the closing of debt and equity financings to…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time. The conference is being held at the St. Regis Hotel in New York. A live webcast can be accessed by visiting the investors section of the Company’s…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 26, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor…